Q-omics provides the consensus-scored TEX22 profile across patient tissues and cancer cell-line models. TEX22 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, TEX22 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, TEX22 RNA expression shows 16,343 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight COAD, and ACC as cancer lineages where TEX22 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TEX22 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TEX22 survival associations across molecular data types. TEX22 RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TEX22 RNA expression–survival associations across cancer types. High TEX22 expression shows unfavorable associations in COAD, ACC, KIRP and UVM, but favorable associations in HNSC and PAAD. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for TEX22 RNA expression.
This table summarizes TEX22 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for TEX22. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TEX22 shows lower tumor expression in THCA and higher tumor expression in COAD, LIHC, HNSC, BLCA and LUSC. The COAD box plot shows higher TEX22 RNA expression in tumor versus normal tissue (log2 FC = +0.501, t-test p < 0.001).
This table shows molecular features associated with TEX22 in patient tissues and cancer cell lines. In patient samples, TEX22 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TEX22 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and SOFT_TISSUE.
